Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Best corrected visual acuity (BCVA)
研究概览
简要总结
Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.
详细描述
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Age-Related macular neovascularization degeneration
排除标准
- •other causes of macular neovascularization degeneration
- •other macular diseases
研究组 & 干预措施
Eylea
Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
干预措施: intravitreal injection (Drug)
BEOVU
Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
干预措施: intravitreal injection (Drug)
结局指标
主要结局
Best corrected visual acuity (BCVA)
时间窗: 12 months
Change in BCVA in LOG MARS(logarithm minimum angle of resolution
次要结局
未报告次要终点
研究者
Tarek Roshdy mohamed Mahgoub ELhamaky
Professor (associate)
Benha University